Novel Smoking Cessation Drug for Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 16, 2016

Study Completion Date

March 9, 2017

Conditions
Smoking Cessation
Interventions
DRUG

Active JNJ Drug

200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week

DRUG

Placebo Pill

Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week

Trial Locations (1)

15213

Western Psychiatric Institute and Clinic and affilated sites, Pittsburgh

All Listed Sponsors
collaborator

University of Pittsburgh

OTHER

collaborator

National Institutes of Health (NIH)

NIH

collaborator

Virginia Commonwealth University

OTHER

lead

K.N. Roy Chengappa

OTHER

NCT02230384 - Novel Smoking Cessation Drug for Schizophrenia | Biotech Hunter | Biotech Hunter